Xenon Pharmaceuticals (XENE) Shares Fall 25% After Hours: Here's Why
Xenon Pharmaceuticals shares fell 25% after hours after pausing new patient enrollment in ongoing psychiatry clinical studies.
Share
Why It Matters
Xenon Pharmaceuticals paused enrolling new patients in brain disorder studies. When a medicine test slows down, investors worry about whether it will work.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.